DK1414465T3 - Inhibition af tumorcellers vækstfaktorafhængighed - Google Patents

Inhibition af tumorcellers vækstfaktorafhængighed

Info

Publication number
DK1414465T3
DK1414465T3 DK01987667T DK01987667T DK1414465T3 DK 1414465 T3 DK1414465 T3 DK 1414465T3 DK 01987667 T DK01987667 T DK 01987667T DK 01987667 T DK01987667 T DK 01987667T DK 1414465 T3 DK1414465 T3 DK 1414465T3
Authority
DK
Denmark
Prior art keywords
inhibition
growth factor
cell growth
tumor cell
factor dependence
Prior art date
Application number
DK01987667T
Other languages
Danish (da)
English (en)
Inventor
Rosemarie Lichtner
Ulrike Fuhrmann
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE10051609A external-priority patent/DE10051609A1/de
Application filed by Schering Ag filed Critical Schering Ag
Application granted granted Critical
Publication of DK1414465T3 publication Critical patent/DK1414465T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK01987667T 2000-10-18 2001-10-17 Inhibition af tumorcellers vækstfaktorafhængighed DK1414465T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US24101000P 2000-10-18 2000-10-18
DE10051609A DE10051609A1 (de) 2000-10-18 2000-10-18 Hemmung der Wachstumsfaktorabhängigkeit von Tumorzellen
PCT/EP2001/012004 WO2002032429A2 (en) 2000-10-18 2001-10-17 Use of inhibitors of progesterone receptor for treating cancer

Publications (1)

Publication Number Publication Date
DK1414465T3 true DK1414465T3 (da) 2007-01-29

Family

ID=26007397

Family Applications (1)

Application Number Title Priority Date Filing Date
DK01987667T DK1414465T3 (da) 2000-10-18 2001-10-17 Inhibition af tumorcellers vækstfaktorafhængighed

Country Status (26)

Country Link
EP (1) EP1414465B1 (ko)
JP (1) JP4335525B2 (ko)
KR (1) KR20030044006A (ko)
CN (1) CN1311833C (ko)
AT (1) ATE339208T1 (ko)
AU (2) AU2002215958B2 (ko)
BG (1) BG107745A (ko)
BR (1) BR0114677A (ko)
CA (1) CA2423013A1 (ko)
CY (1) CY1106289T1 (ko)
CZ (1) CZ299945B6 (ko)
DE (1) DE60123138T2 (ko)
DK (1) DK1414465T3 (ko)
EA (1) EA005945B1 (ko)
EE (1) EE200300156A (ko)
ES (1) ES2272561T3 (ko)
HK (1) HK1071697A1 (ko)
HR (1) HRP20030386A2 (ko)
HU (1) HUP0301461A3 (ko)
IL (2) IL154974A0 (ko)
MX (1) MXPA03002953A (ko)
NO (1) NO20031745L (ko)
NZ (1) NZ545965A (ko)
PL (1) PL366415A1 (ko)
SK (1) SK4752003A3 (ko)
WO (1) WO2002032429A2 (ko)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102006054535A1 (de) * 2006-11-15 2008-05-21 Bayer Schering Pharma Aktiengesellschaft Progesteronrezeptorantagonisten
DE102009034367A1 (de) 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-benzyliden-Derivate, Verfahren zu deren Herstellung und deren Verwendung zur Behandlung von Krankheiten
DE102009034362A1 (de) 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-aryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
DE102009034366A1 (de) 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-methylenoxyalkylenaryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
DE102009034368A1 (de) 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-acyloxyalkylenphenyl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
DE102009034526A1 (de) 2009-07-21 2011-02-10 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-ethinylphenyl-Derivate, Verfahren zu deren Herstellung und deren Verwendung zur Behandlung von Krankheiten
DE102009034525A1 (de) 2009-07-21 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-aryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
DE102010007722A1 (de) 2010-02-10 2011-08-11 Bayer Schering Pharma Aktiengesellschaft, 13353 Progesteronrezeptorantagonisten
DE102010007719A1 (de) * 2010-02-10 2011-08-11 Bayer Schering Pharma Aktiengesellschaft, 13353 Progesteronrezeptorantagonisten

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0466315A3 (en) * 1990-05-30 1992-07-01 Larrian Gillespie Compositions containing xylan sulphates for affecting growth factor function and for inhibiting fibroblast proliferation
US5238950A (en) * 1991-12-17 1993-08-24 Schering Corporation Inhibitors of platelet-derived growth factor
DE19706061A1 (de) * 1997-02-07 1998-08-13 Schering Ag Antigestagen wirksame Steroide mit fluorierter 17alpha-Alkylkette
PE20000129A1 (es) * 1997-12-23 2000-03-11 Schering Ag 11 beta-halogeno-estratrienos sustituidos en 7 alfa, asi como el procedimiento para elaborar preparados farmaceuticos que contienen tales 11 beta-halogeno-estratrienos sustituidos en 7 alfa
FR2789393B1 (fr) * 1999-02-05 2001-10-12 Centre Nat Rech Scient Lactol steroidique

Also Published As

Publication number Publication date
SK4752003A3 (en) 2003-10-07
AU2002215958B2 (en) 2006-08-17
HRP20030386A2 (en) 2005-04-30
NO20031745D0 (no) 2003-04-15
JP2004513094A (ja) 2004-04-30
CY1106289T1 (el) 2011-10-12
EE200300156A (et) 2003-08-15
MXPA03002953A (es) 2003-08-07
KR20030044006A (ko) 2003-06-02
NZ545965A (en) 2007-09-28
AU1595802A (en) 2002-04-29
NO20031745L (no) 2003-04-15
DE60123138D1 (de) 2006-10-26
EP1414465A2 (en) 2004-05-06
CN1551772A (zh) 2004-12-01
AU2002215958C1 (en) 2002-04-29
WO2002032429A2 (en) 2002-04-25
ATE339208T1 (de) 2006-10-15
DE60123138T2 (de) 2007-09-13
PL366415A1 (en) 2005-01-24
IL154974A (en) 2007-05-15
EA200300468A1 (ru) 2003-10-30
IL154974A0 (en) 2003-10-31
EA005945B1 (ru) 2005-08-25
EP1414465B1 (en) 2006-09-13
JP4335525B2 (ja) 2009-09-30
HUP0301461A3 (en) 2010-01-28
BR0114677A (pt) 2003-10-07
HK1071697A1 (en) 2005-07-29
ES2272561T3 (es) 2007-05-01
CN1311833C (zh) 2007-04-25
CZ299945B6 (cs) 2008-12-29
HUP0301461A2 (hu) 2003-10-28
CA2423013A1 (en) 2002-04-25
BG107745A (bg) 2004-01-30
WO2002032429A3 (en) 2004-02-19

Similar Documents

Publication Publication Date Title
EE200300088A (et) Imidasolo-5-üül-2-anilino-pürimidiinid raku proliferatsiooni inhibitsiooni agensitena
HK1071697A1 (en) Inhibition of the growth factor dependency of tumor cells
DK1315694T3 (da) Inhibitorer af alpha-4-medieret celleadhæsion
DK1075260T3 (da) Hidtil ukendte fedtsyreanaloger til behandling af sekundær restenose
DK1360287T4 (da) Fremgangsmåder til modifikation af eukaryotiske celler
BRPI0413305A (pt) compostos azabicìclicos fundidos que inibem o receptor de subtipo de receptor de vanilóide 1 (vr1)
NO20033635L (no) Pyrimidinderivater for inhibering av celle-formering
DK1150714T3 (da) Fremgangsmåder til inhibering af hjernetumorvækst
ID30180A (id) Penggunaan dari turunan-turunan 4-h-1-benzopiran-4-on sebagai inhibitor dari proliferasi sel otot polos
DK1109785T3 (da) Indolderivater og deres anvendelse til behandling af ondartede og andre sygdomme forårsaget af patologisk celleproliferation
NO20003600L (no) Kalium kanal inhibitorer
DK1242060T3 (da) Behandling af metastatisk sygdom
WO2006044869A8 (en) Synthesis of imidazooxazole and imidazothiazole inhibitors of p38 map kinase
DK1325011T3 (da) Fremgangsmåder og forbindelser til behandling af proliferative sygdomme
DE60011755D1 (de) Calciumkanalblocker als antikrebsmittel
YU30003A (sh) Inhibicija zavisnosti faktora rasta na ćelije tumora
BR0317708A (pt) Composto, composição farmacêutica, e, uso de um composto
DK1530482T3 (da) Brug af urease til at hæmme vækst af cancerceller
TR200200494T2 (tr) Yağlı asit sintazı inhibitörleri.
CY1111289T1 (el) Συνθεσεις αναστολεων ογκου που περιεχουν νιτροακριδινη
DE60137417D1 (de) Zellproliferation-inhibitoren
SG148218A1 (en) Compounds for the inhibition of undesired cell proliferation and use thereof
UA90254C2 (ru) Производные пиразола и их применение в качестве ингибиторов рецепторных тирозинкиназ
ECSP003651A (es) Nuevos compuestos espiroheterociclicos utiles como inhibidores reversibles de cisteina-proteasas
DK1307455T3 (da) Inhibitorer af alpha-L-beta-2-medieret celleadhæsion